Aethlon Medical (NASDAQ:AEMD) Stock Price Crosses Below Two Hundred Day Moving Average of $1.18

Shares of Aethlon Medical, Inc. (NASDAQ:AEMDGet Rating) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.18 and traded as low as $0.73. Aethlon Medical shares last traded at $0.75, with a volume of 615,695 shares.

Wall Street Analyst Weigh In

Separately, upgraded Aethlon Medical to a “sell” rating in a report on Tuesday, September 13th.

Aethlon Medical Trading Down 4.7 %

The firm has a fifty day simple moving average of $1.15 and a 200-day simple moving average of $1.18.

Aethlon Medical (NASDAQ:AEMDGet Rating) last posted its quarterly earnings data on Tuesday, June 28th. The medical equipment provider reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.13). Aethlon Medical had a negative return on equity of 59.57% and a negative net margin of 3,542.86%. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $1.02 million. As a group, equities analysts anticipate that Aethlon Medical, Inc. will post 0.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aethlon Medical

An institutional investor recently raised its position in Aethlon Medical stock. Renaissance Technologies LLC grew its position in Aethlon Medical, Inc. (NASDAQ:AEMDGet Rating) by 11.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 270,297 shares of the medical equipment provider’s stock after acquiring an additional 28,097 shares during the quarter. Renaissance Technologies LLC owned approximately 1.75% of Aethlon Medical worth $395,000 as of its most recent filing with the Securities and Exchange Commission. 5.94% of the stock is currently owned by institutional investors and hedge funds.

Aethlon Medical Company Profile

(Get Rating)

Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes.

Featured Articles

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with's FREE daily email newsletter.